ANI Pharmaceuticals Inc (ANIP) CFO exercises 50,000 options and sells stock

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc reports that SVP & CFO Stephen P. Carey exercised stock options for 50,000 shares of common stock at $46.4900 per share on August 12, 2025, then sold 50,000 shares at $86.0700 per share the same day. He continues to hold 180,863 common shares directly.

Insights

Securities Analyst

TL;DR: Insider exercised options and sold an equal number of shares, reducing reported holdings by 50,000 shares.

The filing documents routine Section 16 activity by the CFO: exercise of 50,000 options at $46.49 and an immediate sale of 50,000 common shares at $86.07 on 08/12/2025. The net reported beneficial ownership declined from 230,863 to 180,863 shares. This pattern—exercise followed by sale—is consistent with option liquidity events rather than additional compensation, and the filing includes prior vesting schedule details for the options. There is no disclosure here of any additional compensatory grants or company-wide transactions.

Corporate Governance Expert

TL;DR: Transaction appears procedural and compliant; documents vesting history and is properly reported.

The report indicates compliance with Section 16 reporting: date, amounts, prices, and a signature by attorney-in-fact are present. The earlier vesting schedule is disclosed, showing the options were long-standing. The equal-size exercise and sale suggest a liquidity/monetization of vested options rather than new insider accumulation. No indications of undisclosed related-party transactions or material governance issues are present within this filing.

Insider Trade Summary

Exercise and Sale: 50,000 shares ($1.98M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider CAREY STEPHEN P.

Role SVP & CFO

Sold 50,000 shs ($4.30M)

Approx. gross sale proceeds $4.30M

Approx. exercise cost $2.32M

Approx. pre-tax spread $1.98M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	50,000	$46.49	$2.32M
Exercise	Common Stock	50,000	$46.49	$2.32M
Sale	Common Stock	50,000	$86.07	$4.30M

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 180,863 shares (Direct)

Footnotes (1)

1. F1. 25% of the total options vested on each of May 6, 2017, May 6, 2018, May 6, 2019, and May 6, 2020.

Key Figures

Options Exercised: 50000.0000 shares Exercise Price: $46.4900 per share Shares Sold: 50000.0000 shares +3 more

6 metrics

Options Exercised 50000.0000 shares Stock options exercised on 2025-08-12 at $46.4900 per share

Exercise Price $46.4900 per share Exercise of stock options for 50,000 common shares

Shares Sold 50000.0000 shares Sale of common stock on 2025-08-12 at $86.0700 per share

Sale Price $86.0700 per share Reported price for the 50,000-share common stock sale

Post-Transaction Holding 180,863 shares Direct common stock held by the CFO after the reported transactions

Option Expiration 2026-05-05 Expiration date of the exercised stock option grant

Key Terms

Stock Option (right to buy), derivative security, Sale in open market or private transaction, vested

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Sale in open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

vested financial

"25% of the total options vested on each of May 6, 2017, May 6, 2018, May 6, 2019, and May 6, 2020."

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for its CFO?

Stephen P. Carey, SVP & CFO of ANI Pharmaceuticals, exercised stock options for 50,000 common shares at $46.4900 on August 12, 2025, and sold 50,000 shares at $86.0700 the same day. He retained a direct holding of 180,863 common shares afterward.

How many ANI Pharmaceuticals (ANIP) shares did the CFO sell and at what price?

On August 12, 2025, the CFO sold 50,000 shares of ANI Pharmaceuticals common stock at a reported price of $86.0700 per share. This sale followed the exercise of stock options for the same number of shares at $46.4900 per share.

What was the exercise price of the ANI Pharmaceuticals (ANIP) stock options?

The CFO exercised stock options representing 50,000 shares of ANI Pharmaceuticals common stock at an exercise price of $46.4900 per share. These options were part of a grant that vested in four equal annual installments from 2017 through 2020.

How many ANI Pharmaceuticals (ANIP) shares does the CFO hold after these transactions?

Following the August 12, 2025 option exercise and share sale, the CFO holds 180,863 shares of ANI Pharmaceuticals common stock directly. This post-transaction balance reflects his remaining ownership position reported in the filing’s holdings summary.

When did the ANI Pharmaceuticals (ANIP) stock options involved in the CFO’s trade vest?

The options referenced in the filing vested in four tranches: 25% of the total options vested on each of May 6, 2017, May 6, 2018, May 6, 2019, and May 6, 2020, according to the accompanying footnote disclosure.

What type of transaction code was used for the ANI Pharmaceuticals (ANIP) CFO’s Form 4?

The Form 4 shows an M code for the derivative exercise, indicating an exercise or conversion of a derivative security, and an S code for the common stock sale, indicating a sale in an open market or private transaction on August 12, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/14/2025 - 05:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		50,000	A	$46.49	230,863	D
Common Stock	08/12/2025		S		50,000	D	$86.07	180,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$46.49	08/12/2025		M			50,000	(1)	05/05/2026	Common Stock	50,000	$46.49	0	D

Explanation of Responses:

1. 25% of the total options vested on each of May 6, 2017, May 6, 2018, May 6, 2019, and May 6, 2020.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.